The present invention relates to compounds that inhibit the activity of the proteasome
or the production of proteasomal proteins and promote bone formation and are thus
useful in treating osteoporosis, bone fracture or deficiency, primary or secondary
hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic
bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental
implantation, in subject where this is desirable.
